November 24, 2020
Takeda Pharmaceutical rolled out its PARP inhibitor Zejula (niraparib) on November 20 for the treatment of ovarian cancer in certain settings, making it the second product to be available in the class, after AstraZeneca’s Lynparza (olaparib). The drug is approved...read more